Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IRMD vs DCTH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IRMD Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 8–2 Matrix Metrics)

IRMD Overall Winner 6-Pillar Tally: IRMD 3 – 3 DCTH Matrix Metrics: IRMD 8 – 2 DCTH

As of Nov 16, 2026, iRadimed Corporation (IRMD) is the stronger overall head-to-head candidate over Delcath Systems Inc (DCTH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IRMD carries a Unified Composite Score of 40.3/100 (SELL) at $84.42 (35.0x Forward P/E, 32.3% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin).

  • Growth vs. Quality Trade-Off: IRMD earns the overall head-to-head edge with a stronger Unified Composite Score (40.3/100 SELL vs. DCTH 35.9/100 SELL) and 0.73β · 55% Vol risk profile, whereas DCTH leads top-line expansion (+70.7% YoY revenue growth, 1.60x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although IRMD compares more favorably head-to-head, both IRMD (40.3/100 SELL) and DCTH (35.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: IRMD is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 46.4); meanwhile DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IRMD vs DCTH
IRMD NASDAQ Head-to-Head Winner
iRadimed Corporation
Surgical & Medical Instruments & Apparatus
$84.42
-1.08% 1D
Market Cap $1.1B
TTM Revenue $89M
Forward P/E 35.0x
Beta / 30D Vol 0.73β · 55% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 29.0 Fund 41.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.0%) with fading momentum, RSI 46
RSI-14: 46.4 · SMA20: $85.02 · SMA50: $85.31
DCTH NASDAQ
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.68
-4.23% 1D
Market Cap $743.8M
TTM Revenue $110M
Forward P/E N/M
Beta / 30D Vol 1.63β · 131% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 50.0 Fund 38.0 Flow 60.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 68.9 · SMA20: $16.43 · SMA50: $15.96

6-Pillar Scorecard Institutional Category Breakdown (IRMD 3 – 3 DCTH)

Columns: Metric · IRMD · DCTH
1. Valuation Multiples IRMD
Forward P/E 35.0x N/M
Trailing P/E 45.3x 133.6x
PEG Ratio 4.46x 1.60x
EV / Revenue 12.1x 6.3x
2. Growth & Scale DCTH
Revenue Growth (YoY) +14.2% +70.7%
Earnings Growth (YoY) +18.3% +750.0%
TTM Revenue (USD) $89M $110M
Market Cap $1.1B $743.8M
3. Profitability & Quality IRMD
Gross Margin 75.5% 87.6%
Operating Margin 32.3% 5.2%
Net Profit Margin 26.9% 6.0%
Return on Equity (ROE) 23.4% 5.4%
4. Balance Sheet & Cash Flow IRMD
Cash Generation (TTM) $26M $20M
Cash Flow Margin 28.7% 18.3%
Net Cash / Leverage $8.32 Book/Sh · 23.4% ROE $53M Net Cash
Dividend Yield 0.94% None (0.00%)
5. Options & Positioning DCTH
Options Structure Phase CONSOLIDATION BREAKOUT
Current IV / %ile 34.0% (5th %ile) 109.3% (43rd %ile)
Put/Call OI Skew N/A 0.11x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Distribution ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat DCTH
OpEx & R&D Intensity 43.2% of Rev ($39M) 82.4% of Rev ($91M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IRMD (8) vs DCTH (2)
Institutional Metric IRMD DCTH Criterion Row Edge
Market Capitalization
Scale
$1.1B $743.8M Larger Scale IRMD
Trailing P/E Ratio
Valuation
45.3x 133.6x Lower Multiple IRMD
Forward P/E Ratio
Valuation
35.0x N/M Lower Multiple IRMD
Revenue Growth (YoY)
Growth
+14.2% +70.7% Higher Growth DCTH
Operating Margin (TTM)
Profitability
32.3% 5.2% Higher Margin IRMD
Net Profit Margin
Profitability
26.9% 6.0% Higher Margin IRMD
Return on Equity (ROE)
Capital Efficiency
23.4% 5.4% Higher ROE IRMD
52-Week Range Position
Momentum
26% ($76–$108) 80% ($8–$23) Stronger Trend DCTH
Beta / 30D Volatility
Risk Regime
0.73β · 55% Vol 1.63β · 131% Vol Lower Realized Risk IRMD
Unified Institutional Score
Composite Signal
40.3 / 100 (SELL) 35.9 / 100 (SELL) Higher Composite IRMD
Trailing 12M Revenue (USD)
Operating Scale
$89M $110M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.5% 87.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
4.46x PEG · 12.1x EV/Rev 1.60x PEG · 6.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$26M ($8.32 Book/Sh · 23.4% ROE) $20M ($53M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DCTH +44.13 pp
IRMD: -4.36% · DCTH: +39.77%
3M Horizon DCTH +20.3 pp
IRMD: -3.57% · DCTH: +16.73%
6M Horizon DCTH +82.06 pp
IRMD: -4.6% · DCTH: +77.46%
1Y Horizon DCTH +128.66 pp
IRMD: -0.09% · DCTH: +128.57%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IRMD Revenue DCTH Revenue IRMD Op. Margin DCTH Op. Margin Margin Leader
FY2018 $30M N/A 19.7% N/A IRMD
FY2019 $40M N/A 22.5% N/A IRMD
FY2020 $30M N/A -2.4% N/A IRMD
FY2021 $40M $0M 23.5% -690.0% IRMD
FY2022 $50M $0M 29.3% -1245.1% IRMD
FY2023 $70M $0M 30.6% -1849.0% IRMD
FY2024 $70M $40M 30.0% -33.4% IRMD
FY2025 $80M $90M 31.2% 0.8% IRMD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IRMD CONSOLIDATION
94d in phase · OBV NEUTRAL
Current IV 34.0%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact IRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DCTH BREAKOUT
66d in phase · OBV ACCUMULATION
Current IV 109.3%
IV Percentile 43rd %ile
Put/Call OI Skew 0.11x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IRMD Moat Profile High-Margin Pricing Power Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $1.1B market capitalization and 32.3% operating margin.
OpEx & R&D Reinvestment 43.2% of Rev ($39M)
90D Engineering Disclosures 0 Published
DCTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $743.8M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment 82.4% of Rev ($91M)
90D Engineering Disclosures 0 Published

Investor FAQ IRMD vs DCTH Key Questions & Quantitative Answers

As of Nov 16, 2026, iRadimed Corporation (IRMD) is the stronger overall head-to-head candidate over Delcath Systems Inc (DCTH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IRMD carries a Unified Composite Score of 40.3/100 (SELL) at $84.42 (35.0x Forward P/E, 32.3% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin). Growth vs. Quality Trade-Off: IRMD earns the overall head-to-head edge with a stronger Unified Composite Score (40.3/100 SELL vs. DCTH 35.9/100 SELL) and 0.73β · 55% Vol risk profile, whereas DCTH leads top-line expansion (+70.7% YoY revenue growth, 1.60x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although IRMD compares more favorably head-to-head, both IRMD (40.3/100 SELL) and DCTH (35.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: IRMD is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 46.4); meanwhile DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DCTH leads the Growth & Scale pillar: IRMD posts +14.2% YoY revenue growth and +18.3% YoY earnings growth on $89M TTM revenue (75.5% gross margin, 32.3% operating margin), compared with DCTH at +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IRMD cumulative revenue shifted +166.7% while DCTH shifted +125.0%. In operating R&D and SG&A reinvestment, IRMD deploys 43.2% of Rev ($39M) (0 90-day corporate R&D disclosures) versus 82.4% of Rev ($91M) (0 disclosures) for DCTH.

IRMD screens cheaper on headline valuation multiples. IRMD trades at 35.0x Forward P/E, 45.3x Trailing P/E, 4.46x PEG, and 12.1x EV/Revenue (28.7% FCF margin), whereas DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IRMD (23.4% ROE) versus DCTH (5.4% ROE) capital efficiency.

In options market volatility and institutional positioning, IRMD carries 34.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.73β · 55% Vol realized risk). By comparison, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.